GlassScriptPhysician profile
Georgio Medawar
NPI 1255941720
$9,357.74
in general payments reported to CMS, 2019-2025
33 companies · $2,337 in 2025
The $2,337 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $197 · 2021: $1,218 · 2022: $2,652 · 2023: $1,593 · 2024: $1,361 · 2025: $2,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,997 · Education: $284 · Travel and Lodging: $10.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,996.74 |
| Education | $283.93 |
| Travel and Lodging | $10.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $907.03 | 2022-2025 | Abecma, Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $774.87 | 2021-2025 | Imbruvica, Tecvayli, Erleada |
| Astrazeneca Pharmaceuticals LP | $714.26 | 2020-2025 | Calquence, Tagrisso |
| Genzyme Corporation | $629.35 | 2022-2025 | |
| Eisai INC. | $563.16 | 2020-2023 | |
| Daiichi Sankyo INC. | $488.57 | 2024-2025 | Vanflyta, Datroway |
| Janssen Pharmaceuticals, INC | $470.34 | 2020-2023 | Xarelto |
| Sobi, INC | $371.42 | 2024-2025 | |
| Abbvie INC. | $347.55 | 2022-2025 | |
| Incyte Corporation | $340.39 | 2024-2025 | Jakafi, Niktimvo, Niktimvo |
| Gilead Sciences, INC. | $332.23 | 2022-2023 | Trodelvy |
| Adc Therapeutics America, INC. | $329.95 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $313.10 | 2024-2025 | |
| Glaxosmithkline, LLC. | $308.46 | 2021-2025 | Ojjaara |
| Janssen Scientific Affairs, LLC | $270.23 | 2022-2023 | Tecvayli, Darzalex |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $243.80 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $207.04 | 2022 | |
| Alexion Pharmaceuticals, INC. | $172.08 | 2021-2022 | |
| Stemline Therapeutics INC. | $138.97 | 2025 | Elzonris |
| Takeda Pharmaceuticals U.S.A., INC. | $127.84 | 2022 | |
| Amgen INC. | $125.00 | 2022 | |
| Beigene USA, INC. | $124.98 | 2023 | Brukinsa |
| Celgene Corporation | $124.93 | 2021 | |
| Alcresta Therapeutics, INC. | $124.64 | 2022 | |
| Adaptive Biotechnologies Corporation | $120.24 | 2024 | Clonoseq |
| Exelixis INC. | $119.58 | 2025 | Cabometyx |
| Syndax Pharmaceuticals, INC. | $115.45 | 2025 | |
| Mirati Therapeutics, INC. | $112.25 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $108.22 | 2021 | |
| Rigel Pharmaceuticals, INC. | $96.84 | 2022 | |
| Insmed, INC. | $89.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgio Medawar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.